NCT01879007View on ClinicalTrials.gov

Phase I Trial for Pharmacokinetic Characteristics of Factive 200mg Intravenous Formulation (Gemifloxacin 200mg) With Factive 320mg Tablet Formulation (Gemifloxacin 320mg)

PHASE1CompletedINTERVENTIONAL

Enrollment

16

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

March 31, 2006

Conditions

Infectious Diseases

Interventions

DRUG

Factive® Tab / Factive IV

Trial Locations (1)

Unknown

Asan medical center, Seoul

Sponsors

Lead Sponsor

LG Life Sciences

All Listed Sponsors

lead

LG Life Sciences

INDUSTRY

NCT01879007 - Phase I Trial for Pharmacokinetic Characteristics of Factive 200mg Intravenous Formulation (Gemifloxacin 200mg) With Factive 320mg Tablet Formulation (Gemifloxacin 320mg) | Biotech Hunter | Biotech Hunter